Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: Perspectives and challenges for use in lung diseases

Drug Delivery and Translational Research

Volumn 3, Issue 4, 2013, Pages 352-363

  Howell, M ^a,b   Wang, C ^a,b   Mahmoud, A ^b   Hellermann, G ^a,b   Mohapatra, S S ^a,b   Mohapatra, S ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Chronic respiratory diseases; Nanoparticles; Theranostics

Indexed keywords

CARBON NANOTUBE; DOXORUBICIN; FULLERENE; GADOLINIUM; GOLD NANOPARTICLE; LIPOSOME; METAL OXIDE; NANOPARTICLE; QUANTUM DOT; THERANOSTIC NANOPARTICLE; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYSTIC FIBROSIS; DIAGNOSTIC IMAGING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; HUMAN; LUNG DISEASE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERMEABILITY BARRIER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 84879522760     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0132-4     Document Type: Review

References (113)

1. Organization WH. Prevention and control of chronic respiratory diseases in low and middle-income African countries: A Preliminary Report 2002.
2. Organization WH. Action plan of the Global Alliance against Chronic Respiratory diseases, 2008-20132008.
3. Swai H, Semete B, Kalombo L, Chelule P, Kisich K, Sievers B. Nanomedicine for respiratory diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(3): 255-63. doi: 10. 1002/wnan. 33.
4. Ranjita S, Loaye AS, Khalil M. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci. 2011;14(1): 100-16.
5. Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med (Berl). 2002;80(2): 86-95. doi: 10. 1007/s00109-001-0308-0.
6. Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011;23(36): H217-47. doi: 10. 1002/adma. 201102313.
7. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-)clinical progress. J Control Release. 2012;161(2): 175-87. doi: 10. 1016/j. jconrel. 2011. 09. 063.
8. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3): 284-304. doi: 10. 1016/j. addr. 2009. 11. 002.
9. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1): 16-20. doi: 10. 1021/nn900002m.
10. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11): 592-9. doi: 10. 1016/j. tips. 2009. 08. 004.
11. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjugate Chemistry. 2011;22(10): 1879-903. doi: 10. 1021/bc200151q.
12. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res. 2011;44(10): 979-89. doi: 10. 1021/ar200077p.
13. Gao J, Gu H, Xu B. Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res. 2009;42(8): 1097-107. doi: 10. 1021/ar9000026.
14. Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res. 2011;44(10): 999-1008. doi: 10. 1021/ar200094a.
15. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24(10): 1211-7. doi: 10. 1038/nbt1006-1211.
16. Roy I, Vij N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine. 2010;6(2): 237-44. doi: 10. 1016/j. nano. 2009. 07. 001.
17. Vij N. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential. Expert Opin Drug Deliv. 2011;8(9): 1105-9. doi: 10. 1517/17425247. 2011. 597381.
18. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol. 2006;533(1-3): 341-50. doi: 10. 1016/j. ejphar. 2005. 12. 068.
19. Mastrobattista E, Hennink WE, Schiffelers RM. Delivery of nucleic acids. Pharm Res. 2007;24(8): 1561-3. doi: 10. 1007/s11095-007-9349-6.
20. Xu J, Ganesh S, Amiji M. Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int J Pharm. 2012;427(1): 21-34. doi: 10. 1016/j. ijpharm. 2011. 05. 036.
21. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24-25): 3477-96. doi: 10. 1016/j. biomaterials. 2008. 04. 036.
22. Kumar M, Behera AK, Lockey RF, Zhang J, Bhullar G, De La Cruz CP, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther. 2002;13(12): 1415-25. doi: 10. 1089/10430340260185058.
23. Vij N, Min T, Marasigan R, Belcher CN, Mazur S, Ding H, et al. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnology. 2010;8: 22. doi: 10. 1186/1477-3155-8-22.
24. Rosen JE, Yoffe S, Meerasa A, Verma M, Gu FX. Nanotechnology and diagnostic imaging: new advances in contrast agent technology. Journal of Nanomedicine and Nanotechnology. 2011. doi: 10. 4172/2157-7439. 1000115.
25. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal Bioanal Chem. 2011;399(1): 3-27. doi: 10. 1007/s00216-010-4207-5.
26. Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends in molecular medicine. 2010;16(12): 561-73. doi: 10. 1016/j. molmed. 2010. 09. 004.
27. Aswathy RG, Yoshida Y, Maekawa T, Kumar DS. Near-infrared quantum dots for deep tissue imaging. Anal Bioanal Chem. 2010;397(4): 1417-35. doi: 10. 1007/s00216-010-3643-6.
28. Huang HC, Barua S, Sharma G, Dey SK, Rege K. Inorganic nanoparticles for cancer imaging and therapy. J Contr Release. 2011;155(3): 344-57. doi: 10. 1016/j. jconrel. 2011. 06. 004.
29. Cormode DP, Jarzyna PA, Mulder WJ, Fayad ZA. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev. 2010;62(3): 329-38. doi: 10. 1016/j. addr. 2009. 11. 005.
30. Ordidge KL, Duffy BA, Wells JA, Kalber TL, Janes SM, Lythgoe MF. Imaging the paediatric lung: what does nanotechnology have to offer? Paediatr Respir Rev. 2012;13(2): 84-8. doi: 10. 1016/j. prrv. 2011. 07. 001.
31. Wang C, Ravi S, Martinez GV, Chinnasamy V, Raulji P, Howell M et al. Dual-purpose magnetic micelles for MRI and gene delivery. J Contr Release. 2012. doi: 10. 1016/j. jconrel. 2012. 04. 030.
32. Branca RT, Cleveland ZI, Fubara B, Kumar CS, Maronpot RR, Leuschner C, et al. Molecular MRI for sensitive and specific detection of lung metastases. Proc Natl Acad Sci U S A. 2010;107(8): 3693-7. doi: 10. 1073/pnas. 1000386107.
33. Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials. 2013;34(2): 470-80. doi: 10. 1016/j. biomaterials. 2012. 09. 054.
34. Cho S, Hwang O, Lee I, Lee G, Yoo D, Khang G et al. Chemiluminescent and antioxidant micelles as theranostic agents for hydrogen peroxide associated-inflammatory diseases. Adv Funct Mater. 2012; 22(19): 4038-43. doi: 10. 1002/adfm. 201200773.
35. Marianecci C, Marzio LD, Rinaldi F, Carafa M, Alhaique F. Pulmonary delivery: innovative approaches and perspectives. Journal of Biomaterials and Nanobiotechnology 2011; 2: 567-75. doi: 10. 4236/jbnb. 2011. 225068.
36. Yang W, Peters JI, Williams 3rd RO. Inhaled nanoparticles-a current review. Int J Pharm. 2008;356(1-2): 239-47. doi: 10. 1016/j. ijpharm. 2008. 02. 011.
37. Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. International Journal of Nanomedicine. 2012;7: 1551-72. doi: 10. 2147/IJN. S29997.
38. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2): 158-71. doi: 10. 1016/j. addr. 2008. 11. 002.
39. van der Schans CP. Bronchial mucus transport. Respir Care 2007;52(9): 1150-6; discussion 6-8.
40. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta. 1998;1408(2-3): 79-89.
41. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev. 2009;61(2): 115-27. doi: 10. 1016/j. addr. 2008. 09. 011.
42. Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore U. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Front Immunol. 2012;3: 131. doi: 10. 3389/fimmu. 2012. 00131.
43. Ruge CA, Schaefer UF, Herrmann J, Kirch J, Canadas O, Echaide M et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PloS One 2012; 7(7): e40775. doi: 10. 1371/journal. pone. 0040775.
44. Owens 3rd DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1): 93-102. doi: 10. 1016/j. ijpharm. 2005. 10. 010.
45. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4): 487-95. doi: 10. 1021/mp800032f.
46. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008;3(5): 703-17. doi: 10. 2217/17435889. 3. 5. 703.
47. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3): 161-71. doi: 10. 1038/nrc1566.
48. Chen Z, Ma L, Liu Y, Chen C. Applications of functionalized fullerenes in tumor theranostics. Theranostics. 2012;2(3): 238-50. doi: 10. 7150/thno. 3509.
49. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul. 2001;41: 189-207.
50. Soldati T, Schliwa M. Powering membrane traffic in endocytosis and recycling. Nat Rev Mol Cell Biol. 2006;7(12): 897-908. doi: 10. 1038/nrm2060.
51. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2006;8: 343-75. doi: 10. 1146/annurev. bioeng. 8. 061505. 095735.
52. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008;108(6): 2064-110. doi: 10. 1021/cr068445e.
53. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;60(11): 1241-51. doi: 10. 1016/j. addr. 2008. 03. 014.
54. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol. 2011;165(7-8): 1628-51. doi: 10. 1007/s12010-011-9383-z.
55. Qi L, Gao X. Emerging application of quantum dots for drug delivery and therapy. Expet Opin Drug Deliv. 2008;5(3): 263-7. doi: 10. 1517/17425247. 5. 3. 263.
56. Cai W, Hsu AR, Li ZB, Chen X. Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett. 2007;2(6): 265-81. doi: 10. 1007/s11671-007-9061-9.
57. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol. 2005;16(1): 63-72. doi: 10. 1016/j. copbio. 2004. 11. 003.
58. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2(1): 3-44. doi: 10. 7150/thno. 3463.
59. Kumar R, Kulkarni A, Nagesha DK, Sridhar S. In vitro evaluation of theranostic polymeric micelles for imaging and drug delivery in cancer. Theranostics. 2012;2(7): 714-22. doi: 10. 7150/thno. 3927.
60. Ho YP, Leong KW. Quantum dot-based theranostics. Nanoscale. 2010;2(1): 60-8. doi: 10. 1039/b9nr00178f.
61. Al-Jamal WT, Al-Jamal KT, Bomans PH, Frederik PM, Kostarelos K. Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small. 2008;4(9): 1406-15. doi: 10. 1002/smll. 200701043.
62. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007;7(10): 3065-70. doi: 10. 1021/nl071546n.
63. Kim D, Jon S. Gold nanoparticles in image-guided cancer therapy. Inorganica Chimica Acta. 2012. doi: 10. 1016/j. ica. 2012. 07. 001.
64. Moon GD, Choi SW, Cai X, Li W, Cho EC, Jeong U, et al. A new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release. J Am Chem Soc. 2011;133(13): 4762-5. doi: 10. 1021/ja200894u.
65. Xia Y, Li W, Cobley CM, Chen J, Xia X, Zhang Q, et al. Gold nanocages: from synthesis to theranostic applications. Accounts Chem Res. 2011;44(10): 914-24. doi: 10. 1021/ar200061q.
66. Xiao Y, Hong H, Matson VZ, Javadi A, Xu W, Yang Y, et al. Gold nanorods conjugated with doxorubicin and cRGD for combined anticancer drug delivery and PET imaging. Theranostics. 2012;2(8): 757-68. doi: 10. 7150/thno. 4756.
67. Wang Y, Liu Y, Luehmann H, Xia X, Brown P, Jarreau C, et al. Evaluating the pharmacokinetics and in vivo cancer targeting capability of au nanocages by positron emission tomography imaging. ACS Nano. 2012;6(7): 5880-8. doi: 10. 1021/nn300464r.
68. Kim KS, Park S-J, Lee M-Y, Lim K-G, Hahn SK. Gold half-shell coated hyaluronic acid-doxorubicin conjugate micelles for theranostic applications. Macromol Res 2012; 20(3): 277-82.
69. Murphy CJ, Gole AM, Stone JW, Sisco PN, Alkilany AM, Goldsmith EC, et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Accounts Chem Res. 2008;41(12): 1721-30. doi: 10. 1021/ar800035u.
70. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl. 2010;49(19): 3280-94. doi: 10. 1002/anie. 200904359.
71. Park J, Estrada A, Sharp K, Sang K, Schwartz JA, Smith DK, et al. Two-photon-induced photoluminescence imaging of tumors using near-infrared excited gold nanoshells. Opt Express. 2008;16(3): 1590-9.
72. Chen J, Glaus C, Laforest R, Zhang Q, Yang M, Gidding M, et al. Gold nanocages as photothermal transducers for cancer treatment. Small. 2010;6(7): 811-7. doi: 10. 1002/smll. 200902216.
73. Ramos J, Rege K. Transgene delivery using poly(amino ether)-gold nanorod assemblies. Biotechnol Bioeng. 2012;109(5): 1336-46. doi: 10. 1002/bit. 24408.
74. Li W, Brown PK, Wang LV, Xia Y. Gold nanocages as contrast agents for photoacoustic imaging. Contrast Media and Molecular Imaging. 2011;6(5): 370-7. doi: 10. 1002/cmmi. 439.
75. Terreno E, Uggeri F, Aime S. Image guided therapy: the advent of theranostic agents. J Contr Release. 2012;161(2): 328-37. doi: 10. 1016/j. jconrel. 2012. 05. 028.
76. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4(1): 26-49. doi: 10. 1002/smll. 200700595.
77. Liu Z, Liang XJ. Nano-carbons as theranostics. Theranostics. 2012;2(3): 235-7. doi: 10. 7150/thno. 4156.
78. Liu Z, Li X, Tabakman SM, Jiang K, Fan S, Dai H. Multiplexed multicolor Raman imaging of live cells with isotopically modified single walled carbon nanotubes. J Am Chem Soc. 2008;130(41): 13540-1. doi: 10. 1021/ja806242t.
79. Welsher K, Liu Z, Sherlock SP, Robinson JT, Chen Z, Daranciang D, et al. A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat Nanotechnol. 2009;4(11): 773-80. doi: 10. 1038/nnano. 2009. 294.
80. Bhirde AA, Liu G, Jin A, Iglesias-Bartolome R, Sousa AA, Leapman RD et al. Combining portable Raman probes with nanotubes for theranostic applications. Theranostics 2011; 1: 310-21.
81. Bonner JC. Carbon nanotubes as delivery systems for respiratory disease: do the dangers outweigh the potential benefits? Expet Rev Respir Med. 2011;5(6): 779-87. doi: 10. 1586/ers. 11. 72.
82. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Accounts Chem Res. 2008;41(1): 60-8. doi: 10. 1021/ar700089b.
83. Heller DA, Baik S, Eurell TE, Strano MS. Single-walled carbon nanotube spectroscopy in live cells: towards long-term labels and optical sensors. Adv Mater 2005; 17(23): 2793-9. doi: 10. 1002/adma. 200501343.
84. Liu Z, Yang K, Lee S-T. Single-walled carbon nanotubes in biomedical imaging. J Mater Chem 2011; 21: 586-598. doi: 10. 1039/c0jm02020f.
85. Zerda ADL, Zavaleta C, Keren S, Vaithilingam S, Bodaoati S, Liu Z et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nature Nanotechnology 2008; 3: 557-62. doi: 10. 1038/nnano. 2008. 231.
86. Wang H, Wang J, Deng X, Sun H, Shi Z, Gu Z et al. Biodistribution of carbon single-wall carbon nanotubes in mice. Journal of Nanoscience and Nanotechnology. 2004. doi: 10. 1166/jnn. 2004. 146.
87. Choi JH, Nguyen FT, Barone PW, Heller DA, Moll AE, Patel D, et al. Multimodal biomedical imaging with asymmetric single-walled carbon nanotube/iron oxide nanoparticle complexes. Nano letters. 2007;7(4): 861-7. doi: 10. 1021/nl062306v.
88. Boncel S, Muller KH, Skepper JN, Walczak KZ, Koziol KK. Tunable chemistry and morphology of multi-wall carbon nanotubes as a route to non-toxic, theranostic systems. Biomaterials. 2011;32(30): 7677-86. doi: 10. 1016/j. biomaterials. 2011. 06. 055.
89. Donaldson K, Murphy F, Schinwald A, Duffin R, Poland CA. Identifying the pulmonary hazard of high aspect ratio nanoparticles to enable their safety-by-design. Nanomedicine. 2011;6(1): 143-56. doi: 10. 2217/nnm. 10. 139.
90. Wick P, Clift MJ, Rosslein M, Rothen-Rutishauser B. A brief summary of carbon nanotubes science and technology: a health and safety perspective. ChemSusChem. 2011;4(7): 905-11. doi: 10. 1002/cssc. 201100161.
91. Hendee WR, Morgan CJ. Magnetic resonance imaging. Part I-physical principles. West J Med. 1984;141(4): 491-500.
92. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials. 2011;32(29): 7139-50. doi: 10. 1016/j. biomaterials. 2011. 05. 089.
93. Rastogi R, Gulati N, Kotnala RK, Sharma U, Jayasundar R, Koul V. Evaluation of folate conjugated pegylated thermosensitive magnetic nanocomposites for tumor imaging and therapy. Colloids Surf B Biointerfaces. 2011;82(1): 160-7. doi: 10. 1016/j. colsurfb. 2010. 08. 037.
94. Na HB, Lee JH, An K, Park YI, Park M, Lee IS, et al. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl. 2007;46(28): 5397-401. doi: 10. 1002/anie. 200604775.
95. Le Duc G, Miladi I, Alric C, Mowat P, Brauer-Krisch E, Bouchet A, et al. Toward an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. ACS Nano. 2011;5(12): 9566-74. doi: 10. 1021/nn202797h.
96. Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics. 2009;29(6): 1565-74. doi: 10. 1148/rg. 296095517.
97. Sieber MA, Steger-Hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging. 2009;30(6): 1268-76. doi: 10. 1002/jmri. 21971.
98. Pan D, Caruthers SD, Senpan A, Schmieder AH, Wickline SA, Lanza GM. Revisiting an old friend: manganese-based MRI contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010. doi: 10. 1002/wnan. 116.
99. Pan D, Schmieder AH, Wickline SA, Lanza GM. Manganese-based MRI contrast agents: past, present and future. Tetrahedron. 2011;67(44): 8431-44. doi: 10. 1016/j. tet. 2011. 07. 076.
100. Choi JY, Lee SH, Na HB, An K, Hyeon T, Seo TS. In vitro cytotoxicity screening of water-dispersible metal oxide nanoparticles in human cell lines. Bioprocess Biosyst Eng. 2010;33(1): 21-30. doi: 10. 1007/s00449-009-0354-5.
101. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993;90(23): 11307-11.
102. Nabel EG, Yang Z, Muller D, Chang AE, Gao X, Huang L, et al. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther. 1994;5(9): 1089-94. doi: 10. 1089/hum. 1994. 5. 9-1089.
103. Kong WH, Bae KH, Jo SD, Kim JS, Park TG. Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles. Pharm Res. 2012;29(2): 362-74. doi: 10. 1007/s11095-011-0554-y.
104. Maitani Y, Igarashi S, Sato M, Hattori Y. Cationic liposome (DC-Chol/DOPE = 1: 2) and a modified ethanol injection method to prepare liposomes, increased gene expression. Int J Pharm. 2007;342(1-2): 33-9. doi: 10. 1016/j. ijpharm. 2007. 04. 035.
105. Zhang Y, Li H, Sun J, Gao J, Liu W, Li B, et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm. 2010;390(2): 198-207. doi: 10. 1016/j. ijpharm. 2010. 01. 035.
106. Yallapu MM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res. 2010;27(11): 2283-95. doi: 10. 1007/s11095-010-0260-1.
107. Musacchio T, Laquintana V, Latrofa A, Trapani G, Torchilin VP. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm. 2009;6(2): 468-79.
108. Howell M, Wang C, Sowndharya R, Dixit S, Mohapatra S. Manganese oxide lipid nanoparticles (MLNs) for use as a T1 MRI contrast agent and gene delivery vehicle. J Cont Rel. 2013.
109. Chen Y, Chen H, Zhang S, Chen F, Sun S, He Q, et al. Structure-property relationships in manganese oxide-mesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery. Biomaterials. 2012;33(7): 2388-98. doi: 10. 1016/j. biomaterials. 2011. 11. 086.
110. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol. 2008;295(3): L400-11. doi: 10. 1152/ajplung. 00041. 2008.
111. Alford R, Ogawa M, Choyke PL, Kobayashi H. Molecular probes for the in vivo imaging of cancer. Mol Biosyst. 2009;5(11): 1279-91. doi: 10. 1039/b911307j.
112. Marik J, Tartis MS, Zhang H, Fung JY, Kheirolomoom A, Sutcliffe JL, et al. Long-circulating liposomes radiolabeled with [18 F]fluorodipalmitin ([18 F]FDP). Nucl Med Biol. 2007;34(2): 165-71. doi: 10. 1016/j. nucmedbio. 2006. 12. 004.
113. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408: 239-47.